Uc

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2023-01-06
Clinical Trial Update: Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) [Phase 1, Phase 2]
Open-label, dose-escalation study of pemigatinib in advanced malignancies (FIGHT-101) completed; results posted.